checkAd
    Startseite > Aktien > Zevra Therapeutics > Nachrichten
    Zevra Therapeutics
    Aktie
    ISIN: US4884452065 WKN: A2QLX7 SYM: 1GDA Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    4,3600
     
    EUR
    -4,80 %
    -0,2200 EUR
    Letzter Kurs 14.06.24 Tradegate
    Geldkurs
    14.06.24
    4,2600
     
    EUR
    1.174 STK
    Briefkurs
    14.06.24
    4,4200
     
    EUR
    1.126 STK

    Zevra Therapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
    03.06.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics to Participate at Upcoming Investor Events
    09.05.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
    08.05.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
    01.05.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
    29.04.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
    15.04.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
    10.04.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
    28.03.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
    26.03.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
    25.03.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
    18.03.24 · globenewswire · Zevra Therapeutics
    Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
    04.03.24 · globenewswire · Zevra Therapeutics